The reasons for the delay....Some people on this board pretend that TLT didn't explain the reason for the delay.
I disagree...
In the Jan15,2024 PressRelease TLT said...
'' Based on the FDA's feedback, the Company is currently working with the Clinical Study Sites(''CSS''), a central pathology organization, a biostatistics organization and a regulatory consulting organization to update the the pre-BTD with clinical data clarifications identified by the FDA''.
These steps have to be done in chronological order (TLT has to wait for each organization data,before passing the data to the next organization).
At this point in time TLT can't ask these organizations to rush things, making a mistake at the present time would be very costly for TLT and all of us investors.
Note1)
TLT doesn't need to repeat the above in each PressRelease.
Note2)
1)For those that have warrants, remember that R.Dumoulin has also warrants.
2)There is still time to get BTD approval before these warrants expire.
I like to repeat my prefered quote from Warrent Buffet...
'' No matter how great the talent or efforts, some things just take time''.